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INTRODUCTION
Atrial fibrillation (AF) is the most common 
sustained cardiac arrhythmia and it is 
associated with a substantial increase in 
risk of ischaemic stroke.1,2 Stroke risk is 
reduced by the use of anticoagulants.3–8 
Anticoagulant prophylaxis has been 
recommended by the British Committee for 
Standards in Haematology since 1998 for 
patients with AF at elevated risk of stroke, 
and by the National Institute for Health and 
Care Excellence (NICE) since 2006.9–11 In the 
UK, rates of anticoagulation remain low;12–14 
however, European studies suggest that 
high rates (>80%) of anticoagulation can be 
achieved.15,16 
Underuse of anticoagulants is an 
international problem, which has often 
been attributed to the presence of 
contraindications to treatment, particularly 
bleeding or risk of bleeding.13,17–21 
Conversely, however, several studies in the 
US and Europe have found similar rates 
of prescribing between patients with and 
without contraindications.22–24 To date, 
there have been no comparable studies 
carried out in the UK. Furthermore, there 
has been some inconsistency regarding 
which comorbidities are identified as 
contraindications to anticoagulant 
use. The Medicines and Healthcare 
products Regulatory Agency (MHRA) has 
defined contraindications to warfarin as: 
hypersensitivity to warfarin; haemorrhagic 
stroke; significant bleeding; pregnancy; 
within 72 hours of major surgery with risk of 
severe bleeding; within 48 hours postpartum; 
and drugs where interactions may lead to a 
significantly increased risk of bleeding.25 In 
many studies, other comorbidities, such as 
risk of falls, and possible compliance issues 
are often included as contraindications; 
these may be better regarded as cautions 
for anticoagulant treatment rather than as 
absolute contraindications.25,26
The objective of this study was to 
investigate the relationship between 
contraindications and anticoagulant 
prescribing for AF in UK patients in primary 
care between 2004 and 2015.
METHOD
Data source
The Health Improvement Network is a 
database of anonymised electronic primary 
care records from UK general practices 
using Vision software. It includes coded data 
on patient characteristics, prescriptions, 
consultations, diagnoses, and primary care 
investigations for 3.6 million active patients 
registered at 587 active practices across 
the UK, with more than 85 million patient 
years of data.27 Practices were eligible for 
inclusion in the study from the latest of 
the practice acceptable mortality recording 
date,28 the Vision installation date, and the 
study start date (1 year prior to the first 
index date).
Study design
Twelve sequential cross-sectional analyses 
were performed on 1 May each year from 
Research
Abstract
Background
Underuse of anticoagulants in atrial fibrillation 
(AF) is an international problem, which has 
often been attributed to the presence of 
contraindications to treatment. No studies have 
assessed the influence of contraindications on 
anticoagulant prescribing in the UK.
Aim
To determine the influence of contraindications 
on anticoagulant prescribing in patients with 
AF in the UK.
Design and setting
Cross-sectional analysis of primary care data 
from 645 general practices contributing to 
The Health Improvement Network, a large UK 
database of electronic primary care records.
Method
Twelve sequential cross-sectional analyses were 
carried out from 2004 to 2015. Patients with a 
diagnosis of AF aged ≥35 years and registered for 
at least 1 year were included. Outcome measure 
was prescription of anticoagulant medication.
Results
Over the 12 study years, the proportion of eligible 
patients with AF with contraindications who 
were prescribed anticoagulants increased from 
40.1% (95% confidence interval [CI] = 38.3 to 
41.9) to 67.2% (95% CI = 65.6 to 68.8), and the 
proportion of those without contraindications 
prescribed anticoagulants increased from 42.1% 
(95% CI = 41.6 to 42.6) to 67.7% (95% CI = 67.2 
to 68.1). In patients with a recent history of 
major bleeding or aneurysm, prescribing rates 
increased from 44.3% (95% CI = 42.2 to 46.5) and 
34.8% (95% CI = 29.4 to 40.6) in 2004 to 71.7% 
(95% CI = 69.9 to 73.5) and 63.2% (95% CI = 58.3 
to 67.8) in 2015, respectively, comparable with 
rates in patients without contraindications.
Conclusion
The presence or absence of recorded 
contraindications has little influence on the 
decision to prescribe anticoagulants for the 
prevention of stroke in patients with AF. The 
study analysis suggests that, nationally, 
38 000 patients with AF with contraindications 
are treated with anticoagulants. This has 
implications for patient safety.
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2004 to 2015 (index dates). All analyses 
were undertaken using Stata (version 13).
Analysis
Patients with a diagnosis of AF aged ≥35 years 
on the index date and registered at least 
1 year prior to the index date were included 
in the analysis. The exposure of interest 
was the presence of contraindications to 
anticoagulants. Outcome was treatment 
with anticoagulants.
On each index date, the proportion of 
patients with AF with contraindications 
and the proportions of eligible patients 
prescribed anticoagulants with and without 
contraindications were calculated, with 95% 
confidence intervals (CI). P-values for trends 
over time were calculated using c2 tests; 
P-values for differences between proportions 
of binary variables were calculated using 
two-sample tests for proportions. In primary 
analysis, patients with a CHADS2 score 
≥1 (moderate or high stroke risk) were 
categorised as eligible for anticoagulant 
treatment. CHADS2 score was used to define 
eligibility as it has been in use for longer than 
CHA2DS2-VASc;29,30 in sensitivity analysis, 
patients with a CHA2DS2-VASc score ≥1 were 
categorised as eligible for anticoagulants.
Definitions of variables
A diagnosis of AF was defined by the 
presence of a clinical code for atrial 
fibrillation or atrial flutter at any time prior 
How this fits in
Underuse of anticoagulants in atrial 
fibrillation (AF) is well recognised 
internationally and is often attributed to the 
presence of contraindications. However, 
to date, no analysis has investigated the 
extent to which contraindications influence 
anticoagulant prescribing in the UK. This 
study indicates that contraindications, as 
defined in UK guidance, have little influence 
on the clinician’s decision to prescribe 
anticoagulants to patients with AF with 
moderate to high stroke risk. This has 
important implications for patient safety.
Table 1. Baseline demographic data of patients with atrial fibrillation with and without contraindications to 
anticoagulants, 2004–2015
 Ethnicitya % Townsend scoreb %
  Population Age Sex 
Year Contraindications n mean (SD) male, % White Asian Black Other 1 2 3 4 5 Missing
2004 Without 42 358 75.4 (11.1) 52.5 98.1 0.9 0.4 0.6 23.9 22.5 20.5 17.8 11.5 3.8 
 With 2971 76.7 (9.9) 54.9 97.1 1.5 0.1 1.3 24.5 22.5 21.0 17.4 11.6 3.0
2005 Without 47 892 75.5 (11.2) 52.8 98.1 0.9 0.4 0.6 24.4 22.8 20.5 17.6 11.3 3.4 
 With 3280 76.8 (9.8) 55.8 97.4 1.4 0.1 1.0 24.6 23.5 21.1 16.4 11.8 2.6
2006 Without 52 437 75.6 (11.3) 53.1 98.0 0.9 0.4 0.7 25.0 22.8 20.4 17.3 11.3 3.1 
 With 3502 76.7 (9.9) 56.2 98.0 1.1 0.3 0.7 24.0 22.9 21.4 17.3 11.2 3.2
2007 Without 55 008 76.0 (11.1) 53.3 98.0 0.9 0.4 0.6 25.6 22.9 20.6 17.0 10.9 3.0 
 With 3487 77.1 (9.8) 57.2 97.1 1.2 0.7 1.0 24.7 22.1 22.0 16.9 11.4 3.0
2008 Without 57 916 76.1 (11.0) 53.6 98.0 1.0 0.4 0.6 25.8 23.2 20.5 17.0 11.0 2.6 
 With 3610 77.4 (9.5) 57.3 97.3 1.1 0.7 0.9 24.5 22.1 21.3 18.3 11.4 2.4
2009 Without 61 583 76.2 (11.0) 54.2 97.9 1.0 0.5 0.6 26.1 23.5 20.6 16.8 10.8 2.3 
 With 3969 77.7 (9.5) 57.2 98.1 0.7 0.4 0.9 25.9 22.5 20.1 18.0 11.3 2.3
2010 Without 62 421 76.2 (11.0) 54.6 97.8 1.1 0.5 0.7 26.4 23.5 20.4 16.7 10.8 2.2 
 With 4024 77.4 (9.8) 57.9 98.0 0.9 0.3 0.8 25.8 22.9 21.9 16.4 10.6 2.4
2011 Without 64 090 76.3 (11.1) 54.9 97.8 1.1 0.5 0.6 26.7 23.6 20.5 16.5 10.6 2.2 
 With 4103 77.7 (9.6) 58.1 97.4 1.2 0.5 0.9 26.4 23.6 21.0 16.5 10.2 2.3
2012 Without 65 405 76.3 (11.1) 55.1 97.6 1.2 0.5 0.7 26.5 23.5 20.7 16.3 10.6 2.3 
 With 4248 77.9 (9.7) 58.4 97.1 1.5 0.6 0.9 28.2 22.1 19.3 17.5 10.7 2.3
2013 Without 64 985 76.2 (11.2) 55.8 97.4 1.3 0.6 0.8 26.2 23.2 20.7 16.6 10.8 2.6 
 With 4248 77.8 (10.0) 57.8 96.9 1.5 0.5 1.0 28.2 22.0 19.7 15.9 11.8 2.4
2014 Without 62 855 76.3 (11.2) 56.1 97.4 1.3 0.5 0.8 26.4 23.6 20.7 16.3 10.6 2.4 
 With 4093 78.0 (9.7) 57.8 96.8 1.5 0.6 1.1 27.2 22.7 21.0 16.3 10.2 2.6
2015 Without 54 100 76.2 (11.2) 56.6 97.6 1.1 0.5 0.8 25.6 23.5 20.7 16.7 10.8 2.6 
 With 3353 77.8 (10.0) 59.1 98.0 1.0 0.4 0.6 26.8 23.5 20.6 17.0 9.5 2.7
aWhere recorded; ethnicity was missing in 59.2% of the patient records (decreasing from 74.4% in 2004 to 54.2% in 2015). b1 = Least deprived, 5 = Most deprived. 
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to the index date, excluding patients with 
a more recent clinical code indicating that 
AF had resolved. Current anticoagulant 
treatment was defined by a record of a 
relevant prescription within 90 days prior to 
the index date or a clinical code indicating 
the patient was receiving anticoagulant 
therapy within 365 days prior to the index 
date.
Contraindications to anticoagulants were 
defined in accordance with MHRA and NICE 
evidence.25,26 Contraindications specific to 
anticoagulants other than warfarin, such 
as novel oral anticoagulants (NOACs) (for 
example, liver disease), were not included, 
as these do not preclude treatment with 
warfarin. Short-term contraindications 
(within 72 hours of surgery or 48 hours 
postpartum) and cautions for anticoagulant 
use were not included. Contraindications 
were defined as: a clinically coded diagnosis 
within the 2 years prior to the index date 
of haemorrhagic stroke, major bleeding 
(gastrointestinal, intracranial, intraocular, 
retroperitoneal), bleeding disorders 
(haemophilia, other haemorrhagic 
disorders, thrombocytopenia), peptic 
ulcer, oesophageal varices, aneurysm, or 
proliferative retinopathy; a record of allergy 
or adverse reaction to anticoagulants 
ever prior to the index date; a record of 
pregnancy in the 9 months prior to the 
index date; or severe hypertension with a 
mean (of the three most recent measures 
in the last 3 years prior to the index date) 
systolic blood pressure >200 mmHg or 
diastolic blood pressure >120 mmHg.
CHADS2 scores were calculated by 
adding one point each for a history of 
congestive heart failure, hypertension, age 
≥75 years, and diabetes, and two points for 
a history of stroke or transient ischaemic 
attack (TIA). CHA2DS2-VASc scores were 
calculated by adding one point each 
for a history of congestive heart failure, 
hypertension, diabetes, vascular disease, 
age 65–74 years, and female sex (if another 
risk factor was present, otherwise 0), and 
two points each for age ≥75 years and 
history of stroke, TIA, or thromboembolism. 
History of congestive heart failure, stroke, 
TIA, thromboembolism, vascular disease, 
and diabetes were defined by a clinical 
code recorded ever prior to the index date, 
excluding patients with diabetes with a 
later record indicating diabetes resolved. 
Hypertension was defined as either a 
current (previous 90 days) prescription of 
antihypertensive drugs or the mean of the 
three most recent systolic blood pressures 
in the last 3 years ≥160 mmHg.
RESULTS
A total of 166 136 patients with AF from 645 
practices were included in the study. As an 
individual could contribute to the analysis 
in more than 1 year, a total of 735 938 
records of patients with AF were included 
in the analysis across the 12 index dates, 
with a median of 63 539 (interquartile range 
[IQR] = 56 696–67 571) patients per year. 
The mean age of patients with AF across all 
years was 76.2 (standard deviation [SD] 11.0) 
years; 54.7% (n = 402 354 out of 735 938) 
were male. Baseline characteristics are 
shown in Table 1: patients with AF with 
contraindications were on average 1.4 
(95% CI = 1.3 to 1.5) years older and 2.3% 
(95% CI = 2.4 to 3.4) more were male.
Around 6% of patients had 
contraindications to anticoagulation and 
this changed little over the 12-year period 
(range = 5.8 to 6.6%). The most common 
contraindication was major bleeding: 
4.4% (95% CI = 4.2 to 4.6) of patients with 
AF in 2015. The prevalence of individual 
contraindications remained reasonably 
constant from 2004 to 2015, except for 
declining frequency of peptic ulcer from 
0.64% to 0.35% (P<0.001) and of severe 
hypertension from 0.22% to 0.02% 
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Figure 1. Prevalence of contraindications to 
anticoagulants in patients with atrial fibrillation by 
age category, 2015.
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(P<0.001) (Appendix 1). The prevalence of all 
contraindications tended to increase with 
age (Figure 1).
The proportion of eligible patients 
(with a CHADS2 score ≥1) prescribed 
anticoagulants increased from 2004 
to 2015. However, in every year similar 
proportions with contraindications 
and without contraindications were 
prescribed anticoagulants (Figure 2). 
In 2004, 40.1% (95% CI = 38.3 to 41.9) of 
those with and 42.1% (95% CI = 41.6 to 
42.6) of those without contraindications 
were prescribed anticoagulants; in 2015, 
this increased to 67.2% (95% CI = 65.6 to 
68.8) and 67.7% (95% CI = 67.2 to 68.1), 
respectively (Appendix 2). The difference 
between the proportion of patients with 
and without contraindications who were 
prescribed anticoagulants in 2015 was 
not statistically significant: P = 0.595. 
In 2015, the interquartile range (IQR) for 
the proportion of eligible patients with 
AF prescribed anticoagulants by general 
practice was 52.6–80.0% in patients with 
contraindications and 61.8–72.4% in 
patients without contraindications.
Defining eligibility for anticoagulants 
using the CHA2DS2-VASc score (≥1) made 
no difference to the observed trends or to 
differences in treatment between those with 
and without contraindications (Appendix 3).
The proportions of patients with AF who 
were prescribed anticoagulants, and trends 
in prescribing, were similar between patients 
with the most common contraindications — 
major bleeding and aneurysm — and patients 
without contraindications (Appendix 4). In 
eligible patients with AF with a recent history 
of major bleeding or aneurysm, prescribing 
rates increased from 44.3% (95% CI = 42.2 to 
46.5) and 34.8% (95% CI = 29.4 to 40.6) in 2004 
to 71.7% (95% CI = 69.9 to 73.5) and 63.2% 
(95% CI = 58.3 to 67.8) in 2015, respectively. 
These were comparable to prescribing 
rates in eligible patients with AF without 
contraindications: 42.1% (95% CI = 41.6 to 
42.6) and 67.7% (95% CI = 67.2 to 68.1) in 
2004 and 2015 respectively. The proportion 
of patients with AF with less common 
contraindications who were prescribed 
anticoagulants was lower across the whole 
period but also increased over time. In 2015, 
anticoagulants were prescribed to 44.1% 
(95% CI = 32.8 to 56.1) with an adverse 
reaction, 54.3% (95% CI = 47.5 to 61.0) with 
gastrointestinal disorders, 38.1% (95% 
CI = 31.9 to 44.8) with haemorrhagic stroke, 
54.5% (95% CI = 25.6 to 80.7) with severe 
hypertension, and 83.3% (95% CI = 58.2 to 
94.7) with proliferative retinopathy. 
Treatment of patients with AF with 
NOACs began in 2010 and their use has 
increased steadily since then (Appendix 5). 
In 2015, slightly more patients with 
contraindications were prescribed NOACs 
than vitamin K antagonists: 19.0% versus 
17.4% (P = 0.061). 
DISCUSSION
Summary
This analysis demonstrates that patients with 
AF with contraindications are just as likely 
to be prescribed anticoagulants as those 
without contraindications. The proportion of 
patients with AF with contraindications who 
are prescribed anticoagulants is increasing 
over time, mirroring the rise in prescribing 
to those without contraindications. This 
suggests that, in practice, the presence or 
absence of most contraindications has little 
or no influence on the clinician’s decision to 
prescribe anticoagulants to patients with AF.
Strengths and limitations
The analysis was performed in a 
large general practice dataset that is 
generalisable to the UK population; the 
clinical data are routine and therefore 
comprise the information that GPs use for 
clinical decision making. AF diagnosis was 
often corroborated in the patient records, 
although it was not possible to confirm 
all diagnoses of AF; however, in a sample 
of 131 patients with AF diagnosed in UK 
primary care in 2006, 84% were found to 
have either a primary or secondary care 
electrocardiogram confirmation of their 
diagnosis.31 Care was taken to exclude 
patients with ‘AF resolved’.
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Some anticoagulated patients may 
be omitted if they are managed entirely in 
hospital, and treatment rates may therefore 
be underestimated. However, this is 
attenuated by the inclusion of clinical codes 
for anticoagulant/international normalised 
ratio monitoring, in addition to prescription 
information, in the definition of anticoagulant 
use; furthermore, most anticoagulants 
are prescribed in primary care, and any 
underestimation is therefore likely to be small.
Most variables were defined by the 
presence of relevant clinical codes in the 
primary care record. Diagnoses that 
are part of the UK Quality and Outcomes 
Framework assessment are likely to be 
well recorded for most/all of the study 
period; clinically significant conditions, 
such as major bleed, which have important 
implications for prescribing of drugs other 
than anticoagulants, are also likely to be well 
recorded. However, recording of other medical 
conditions may be incomplete. There is no 
independent corroboration of the presence of 
contraindications, but the information used in 
the study is the same as that used by GPs for 
decision making, and contraindication rates 
are comparable with those found in other 
studies.16,23 Some contraindications may 
be inaccurate, for example, haemorrhagic 
stroke may be reclassified as ischaemic 
stroke; however, diagnosis of haemorrhagic 
stroke is generally accurate in primary care 
records.32 Some contraindications may be the 
result of previous anticoagulant treatment.
In addition to consideration of the 
presence/absence of contraindications, the 
decision to treat may also be influenced 
by cautions for anticoagulant use, such as 
the risk of falls or issues with treatment 
compliance. However, this should reduce 
rather than increase the likelihood of 
prescribing anticoagulants. Additionally, 
no information on patient preferences was 
available, although patients are often guided 
by GPs with regard to preventive medicine.33
Comparison with existing literature
Contraindications have often been 
cited as a reason for not prescribing 
anticoagulants.17,19–21 However, this analysis 
suggests that contraindications do not stop 
clinicians from prescribing; this agrees 
with findings from studies in the US and 
Europe.22–24 It is unclear why many patients 
with AF without contraindications are not 
prescribed anticoagulants, while patients 
with contraindications are. 
Implications for research and practice 
The study’s findings have important 
implications for patient care. Alongside 
underuse of anticoagulants in patients with 
AF, there may be significant overtreatment 
of patients with contraindications. Based on 
the recorded prevalence of AF in recent data 
there are 1.03 million UK patients diagnosed 
with AF.34,35 Of these, 59 000 (5.8%) have 
contraindications to anticoagulants, 57 000 
(96%) of those with contraindications have 
a CHADS2 score ≥1, and 38 000 (67.2%) 
are treated. This represents a significant 
concern for patient safety.
Although the balance of risks and 
benefits of using anticoagulants is 
favourable in patients with AF who do 
not have contraindications, it is unclear 
whether this also applies to patients with 
contraindications. Further work is needed 
to determine whether outcomes are worse 
among contraindicated patients with AF 
who are treated with anticoagulants than 
among those who are not, or whether 
the reduced stroke risk offsets any other 
potential adverse events. There is some 
recent evidence suggesting that resuming 
anticoagulant therapy may be beneficial 
in patients with AF who survive warfarin-
related intracranial haemorrhage.36,37
Further work is needed to determine 
which patients with contraindications may 
still benefit from anticoagulant treatment. 
Qualitative research is needed in order to 
reveal the reasons why clinicians prescribe 
to patients with contraindications and why 
they do not prescribe to many patients 
without.
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Appendix 1. Prevalence of contraindications in patients with atrial fibrillation (AF), 2004–2015
 Contraindications (%)
 All  Adverse Peptic Major Haemorrhagic  Oesophageal  Proliferative  
Year AF (n) Any reaction ulcer bleeding stroke Hypertension varices Aneurysm retinopathy Pregnancy
2004 45 329 6.55 0.11 0.64 4.80 0.31 0.22 0.04 0.66 0.04 0.01
2005 51 172 6.41 0.17 0.55 4.74 0.33 0.16 0.04 0.67 0.05 0.00
2006 55 939 6.26 0.17 0.51 4.60 0.34 0.11 0.03 0.71 0.05 0.00
2007 58 495 5.96 0.15 0.49 4.38 0.33 0.09 0.02 0.69 0.04 0.00
2008 61 526 5.87 0.16 0.49 4.33 0.30 0.06 0.03 0.67 0.04 0.00
2009 65 552 6.05 0.14 0.46 4.53 0.27 0.06 0.03 0.75 0.04 0.01
2010 66 445 6.06 0.14 0.37 4.58 0.29 0.06 0.03 0.77 0.06 0.00
2011 68 193 6.02 0.13 0.43 4.55 0.30 0.05 0.03 0.70 0.05 0.00
2012 69 653 6.10 0.10 0.44 4.60 0.32 0.04 0.03 0.74 0.05 0.01
2013 69 233 6.14 0.13 0.40 4.60 0.35 0.03 0.03 0.75 0.04 0.01
2014 66 948 6.11 0.14 0.36 4.59 0.40 0.02 0.03 0.75 0.03 0.00
2015 57 453 5.84 0.12 0.35 4.39 0.37 0.02 0.03 0.70 0.03 0.00
Appendix 2. Proportion of eligible (CHADS2 ≥1) patients with atrial fibrillation (AF) with and without 
contraindications prescribed anticoagulants, 2004–2015
 Patients with AF without contraindications Patients with AF with contraindications P-value 
 All CHADS2 ≥1 Anticoagulants All CHADS2 ≥1 Anticoagulants for
Year n n n % (95% CI) n n n % (95% CI) difference
2004 42 358 38 447 16 202 42.1 (41.6 to 42.6) 2971 2795 1120 40.1 (38.3 to 41.9) 0.0323
2005 47 892 43 692 19 051 43.6 (43.1 to 44.1) 3280 3115 1297 41.6 (39.9 to 43.4) 0.0325
2006 52 437 48 000 21 632 45.1 (44.6 to 45.5) 3502 3331 1436 43.1 (41.4 to 44.8) 0.0282
2007 55 008 51 008 24 416 47.9 (47.4 to 48.3) 3487 3340 1559 46.7 (45.0 to 48.4) 0.1821
2008 57 916 54 012 26 913 49.8 (49.4 to 50.2) 3610 3455 1696 49.1 (47.4 to 50.8) 0.3993
2009 61 583 57 689 29 424 51.0 (50.6 to 51.4) 3969 3815 1919 50.3 (48.7 to 51.9) 0.4002
2010 62 421 58 626 30 415 51.9 (51.5 to 52.3) 4024 3855 1967 51.0 (49.4 to 52.6) 0.3034
2011 64 090 60 259 31 745 52.7 (52.3 to 53.1) 4103 3953 1988 50.3 (48.7 to 51.8) 0.0036
2012 65 405 61 512 33 578 54.6 (54.2 to 55.0) 4248 4104 2234 54.4 (52.9 to 56.0) 0.8488
2013 64 985 60 995 35 640 58.4 (58.0 to 58.8) 4248 4098 2327 56.8 (55.3 to 58.3) 0.0384
2014 62 855 58 943 36 984 62.7 (62.4 to 63.1) 4093 3956 2388 60.4 (58.8 to 61.9) 0.0027
2015 54 100 50 677 34 286 67.7 (67.2 to 68.1) 3353 3226 2168 67.2 (65.6 to 68.8) 0.5947
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Appendix 3. Proportion of patients with atrial fibrillation (AF) with a CHA2DS2-VASc ≥1 score with and 
without contraindications prescribed anticoagulants, 2004–2015
 Patients with AF without contraindications Patients with AF with contraindications P-value
 All CHA2DS2-VASc ≥1 Anticoagulants All CHA2DS2-VASc ≥1 Anticoagulants for
Year n n n % (95% CI) n n n % (95% CI) difference
2004 42 358 40 309 16 848 41.8 (41.3 to 42.3) 2971 2897 1164 40.2 (38.4 to 42.0) 0.0881
2005 47 892 45 632 19 747 43.3 (42.8 to 43.7) 3280 3207 1340 41.8 (40.1 to 43.5) 0.0994
2006 52 437 50 020 22 338 44.7 (44.2 to 45.1) 3502 3428 1484 43.3 (41.6 to 45.0) 0.1191
2007 55 008 52 949 25 192 47.6 (47.2 to 48.0) 3487 3418 1595 46.7 (45.0 to 48.3) 0.3002
2008 57 916 55 925 27 677 49.5 (49.1 to 49.9) 3610 3549 1741 49.1 (47.4 to 50.7) 0.6165
2009 61 583 59 569 30 147 50.6 (50.2 to 51.0) 3969 3922 1973 50.3 (48.7 to 51.9) 0.7135
2010 62 421 60 383 31 080 51.5 (51.1 to 51.9) 4024 3956 2017 51.0 (49.4 to 52.5) 0.5538
2011 64 090 62 042 32 361 52.2 (51.8 to 52.6) 4103 4047 2019 49.9 (48.3 to 51.4) 0.0051
2012 65 405 63 342 34 169 53.9 (53.6 to 54.3) 4248 4187 2261 54.0 (52.5 to 55.5) 0.9431
2013 64 985 62 813 36 220 57.7 (57.3 to 58.0) 4248 4184 2363 56.5 (55.0 to 58.0) 0.1328
2014 62 855 60 690 37 535 61.8 (61.5 to 62.2) 4093 4040 2425 60.0 (58.5 to 61.5) 0.0210
2015 54 100 52 189 34 844 66.8 (66.4 to 67.2) 3353 3296 2196 66.6 (65.0 to 68.2) 0.8697
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Appendix 5. Type of anticoagulant prescribed to eligible patients with atrial fibrillation with and without 
contraindications to anticoagulants, 2004–2015
 Vitamin K antagonists
   Prescribed  
  CHADS2 ≥1 anticoagulant Warfarin Parenteral Other NOACs Multiple
Year Contraindications n n n (%) n (%) n (%) n (%) n (%)
2004 With 2795 1120 1113 (99.4) 0 7 (0.6) 0 0 
 Without 41 242 16 202 16 072 (99.2) 14 (0.1) 115 (0.7) 0 1 (0.0)
2005 With 3115 1297 1284 (99.0) 5 (0.4) 7 (0.5) 0 1 (0.1) 
 Without 46 807 19 051 18 906 (99.2) 23 (0.1) 119 (0.6) 0 3 (0.0)
2006 With 3331 1436 1418 (98.7) 6 (0.4) 12 (0.8) 0 0 
 Without 51 331 21 632 21 466 (99.2) 41 (0.2) 123 (0.6) 0 2 (0.0)
2007 With 3340 1559 1541 (98.8) 8 (0.5) 10 (0.6) 0 0 
 Without 54 348 24 416 24 235 (99.3) 48 (0.2) 130 (0.5) 0 3 (0.0)
2008 With 3455 1696 1673 (98.6) 9 (0.5) 12 (0.7) 0 2 (0.1) 
 Without 57 467 26 913 26 695 (99.2) 72 (0.3) 139 (0.5) 0 7 (0.0)
2009 With 3815 1919 1894 (98.7) 11 (0.6) 14 (0.7) 0 0 
 Without 61 504 29 424 29 165 (99.1) 101 (0.3) 152 (0.5) 0 6 (0.0)
2010 With 3855 1967 1938 (98.5) 17 (0.9) 11 (0.6) 0 1 (0.1) 
 Without 62 481 30 415 30 127 (99.1) 122 (0.4) 151 (0.5) 4 (0.0) 11 (0.0)
2011 With 3953 1988 1947 (97.9) 24 (1.2) 12 (0.6) 1 (0.1) 4 (0.2) 
 Without 64 212 31 745 31 434 (99.0) 138 (0.4) 154 (0.5) 5 (0.0) 14 (0.0)
2012 With 4104 2234 2174 (97.3) 26 (1.2) 12 (0.5) 17 (0.8) 5 (0.2) 
 Without 65 616 33 578 33 113 (98.6) 195 (0.6) 148 (0.4) 102 (0.3) 20 (0.1)
2013 With 4098 2327 2192 (94.2) 28 (1.2) 10 (0.4) 94 (4.0) 3 (0.1) 
 Without 65 093 35 640 34 252 (96.1) 190 (0.5) 137 (0.4) 1034 (2.9) 27 (0.1)
2014 With 3956 2388 2113 (88.5) 39 (1.6) 6 (0.3) 227 (9.5) 3 (0.1) 
 Without 62 899 36 984 33 579 (90.8) 211 (0.6) 127 (0.3) 3037 (8.2) 30 (0.1)
2015 With 3226 2168 1719 (79.3) 29 (1.3) 6 (0.3) 411 (19.0) 3 (0.1) 
 Without 53 903 34 286 28 018 (81.7) 185 (0.5) 84 (0.2) 5959 (17.4) 40 (0.1)
NOACs = novel oral anticoagulants.
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